Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.50 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CBX7 | O95931 | 1/20 | 0.39 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495393 | 0.84 | KMT2A (0.57) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5857380 | 0.83 | KCNMA1 (0.71) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5858002 | 0.82 | KCNQ3 (0.74) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5981621 | 0.82 | KMT2A (0.46) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5857998 | 0.81 | KMT2A (0.53) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL27380545 | 0.80 | KMT2A (0.43) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL2497604 | 0.79 | KMT2A (0.51) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL2497429 | 0.79 | CBX7 (0.52) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL11048112 | 0.79 | MMP2 (0.47) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5860255 | 0.78 | KMT2A (0.50) | KMT2AKCNMA1KCNQ3KCNQ2KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015242-B2 | Methods for treating hyperactive gastrointestinal motility | WYETH (US) | 2006-03-21 | — | — | US | claimed |
| EP-1634594-A1 | Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators | NeuroSearch A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| EP-1303269-B1 | USE OF 3-SUBSTITUTED OXINDOLE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | NEUROSEARCH AS (DK) | 2005-12-07 | — | — | EP | claimed |
| CN-1222288-C | Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators | NEUROSEARCH AS (DK) | 2005-10-12 | — | — | CN | claimed |
| US-20040029949-A1 | Methods for treating hyperactive gastric motility | WYETH (US) | 2004-02-12 | — | — | US | claimed |
| CN-1469739-A | Method for modulating bladder function | — | 2004-01-21 | — | — | CN | claimed |
| US-20030181507-A1 | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators | NEUROSEARCH A/S (DK) | 2003-09-25 | — | — | US | claimed |
| CN-1438885-A | Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators | NEUROSEARCH AS (DK) | 2003-08-27 | — | — | CN | claimed |
| EP-1326597-A2 | METHODS FOR MODULATING BLADDER FUNCTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| US-20020183395-A1 | Methods for treating hyperactive gastric motility | WYETH | 2002-12-05 | — | — | US | claimed |
| WO-2002080898-A2 | METHODS FOR TREATING HYPERACTIVE GASTRIC MOTILITY | WYETH (US) | 2002-10-17 | — | — | WO | claimed |
| WO-2002032419-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2002-04-25 | — | — | WO | claimed |
| US-6348486-B1 | TREATMENT OF INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-19 | — | — | US | claimed |
| EP-0747354-B1 | 3-Substituted oxindole derivatives as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2000-08-16 | — | — | EP | claimed |
| EP-0747354-A1 | 3-Substituted oxindole derivatives as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | claimed |
| US-5565483-A | ADMINISTERING AS THERAPY FOR ISCHEMIA, CONVULSIONS OR ASTHMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-0747354-B1 | 3-Substituted oxindole derivatives as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5565483-A | ADMINISTERING AS THERAPY FOR ISCHEMIA, CONVULSIONS OR ASTHMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029949-A1 | Methods for treating hyperactive gastric motility | KCNQ5, KCNQ3, KCNQ4 | KMT2A 277/4885KCNMA1 47/4885KCNQ3 2/4885 |
| US-20020183395-A1 | Methods for treating hyperactive gastric motility | KCNQ5, KCNQ3, KCNQ4 | KMT2A 254/4885KCNMA1 48/4885KCNQ3 2/4885 |
| US-20030181507-A1 | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators | KCNQ1, KCNQ2, KCNQ3 | KMT2A 262/4885KCNMA1 36/4885KCNQ3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.